Semaglutide vs tirzepatide

Semaglutide acts on GLP-1 receptors, while tirzepatide acts on both GLP-1 and GIP receptors. These signals help control appetite and blood sugar. Weekly injections of either drug may support weight management in eligible adults. Results vary. A physician licensed in your state decides which treatment, if any, is appropriate.

Tirzepatide produced greater average weight loss than semaglutide in a head-to-head trial of specific weekly injection doses in adults with obesity without diabetes. Results vary. That finding does not predict your response or prove that any compounded preparation will deliver the results seen with the studied products.

For approved adult weight management products, eligibility generally starts at a body mass index of 30, or 27 with a weight-related health condition. These numbers alone do not establish eligibility. A physician licensed in your state must review your health history, medicines, and the risks of semaglutide or tirzepatide.

Semaglutide and tirzepatide share common digestive side effects, including nausea, vomiting, diarrhea, constipation, and stomach discomfort. Neither is always easier to tolerate. Side effects often occur when treatment starts or the dose increases. Severe or lasting symptoms need medical review, and some symptoms require urgent care rather than an online message.

Weekly injections are available for both semaglutide and tirzepatide. Semaglutide also has oral products, while tirzepatide does not have an FDA-approved oral option. Oral semaglutide has product-specific uses and dosing rules. Do not assume a tablet replaces an injection or that Verra offers every form discussed in this guide.

Some people notice appetite changes early, but weight changes are better assessed over months rather than days. Results vary. Both semaglutide and tirzepatide usually begin at a low dose that increases gradually. Your physician will consider your progress, side effects, and time at a tolerated dose before judging the treatment.

Do not take semaglutide and tirzepatide together. A physician may consider a switch, but their doses are not directly equivalent. Your next dose and start date depend on your current treatment, side effects, and any gap in use. Do not reuse an old dose schedule for the new medication.

Neither drug should be used for weight loss during pregnancy. Semaglutide should be stopped at least two months before a planned pregnancy. Tirzepatide can reduce the effectiveness of birth control pills after starting or increasing the dose. Discuss pregnancy plans and contraception with your physician before choosing either treatment.

After stopping semaglutide or tirzepatide, appetite may increase and weight regain can occur. Results vary. Blood sugar may also rise if you have diabetes. Plan any stop with your physician, especially if you take other diabetes medicines. Restarting after a gap may require a lower dose and new instructions.

Check each treatment page for the current medication price and available options. Verra's online visit fee is $99, and its video visit fee is $149. Medication is charged only after physician approval. Verra does not bill insurance. Some states or medications require a video visit rather than an online visit.